Division of Thoracic Surgery, Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Division of Transplant Surgery, Department of Surgery, New York University Grossman School of Medicine and Langone Health, New York, New York.
J Surg Res. 2024 Oct;302:175-185. doi: 10.1016/j.jss.2024.07.043. Epub 2024 Aug 3.
Transplants with hearts and lungs from donors with hepatitis C virus (HCV D+) have been proven safe and effective since development of direct-acting antivirals, yet the presence of HCV + persists as a reason to decline organs.
We identified adult candidates listed January 1, 2015-March 8, 2023 for heart or lung transplant using the Scientific Registry of Transplant Recipients. We identified individual-level and center-level characteristics associated with listing to consider HCV D+ offers using multilevel logistic regression in a multivariable framework.
Over the study period, the annual percentage of candidates willing to consider HCV D+ offers increased for both heart (9.5%-74.3%) and lung (7.8%-59.5%), as did the percentage of centers listing candidates for HCV D+ heart (52.9%-91.1%) and lung (32.8%-82.8%) offers. Candidates at centers with more experience with HCV D+ transplants were more likely to consider HCV D+ organ offers. After adjustment, listing center explained 70% and 78% of the residual variance in willingness to consider HCV D+ hearts and lungs, respectively.
Although listing for consideration of HCV D+ offers has increased, it varies by transplant center. Center-level barriers to consideration of HCV D+ organs reduce recipients' transplant access.
自直接作用抗病毒药物问世以来,从丙型肝炎病毒(HCV D+)供体中移植的心脏和肺脏已被证明是安全有效的,但 HCV+的存在仍然是拒绝器官的一个原因。
我们使用移植受者科学登记处,确定了 2015 年 1 月 1 日至 2023 年 3 月 8 日期间列出的接受心脏或肺脏移植的成年候选者。我们确定了与列出 HCV D+供体相关的个体和中心特征,以便在多变量框架中使用多水平逻辑回归来考虑 HCV D+的供体。
在研究期间,无论是心脏(9.5%-74.3%)还是肺脏(7.8%-59.5%),愿意考虑 HCV D+供体的候选者的比例每年都有所增加,同时愿意列出 HCV D+心脏(52.9%-91.1%)和肺脏(32.8%-82.8%)供体的中心比例也有所增加。在有更多 HCV D+移植经验的中心的候选者更有可能考虑 HCV D+器官供体。调整后,中心解释了愿意考虑 HCV D+心脏和肺脏的 70%和 78%的剩余方差。
尽管考虑 HCV D+供体的意愿有所增加,但这因移植中心而异。考虑 HCV D+器官的中心障碍减少了受者的移植机会。